Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
32 participants
INTERVENTIONAL
2025-08-01
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia
NCT06799611
Phase I Study to Evaluate rhTPO in Healthy Caucasian Volunteers
NCT06630494
Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy
NCT07091370
Prospective Evaluation of Diagnosis and Treatment of Patients With Autoimmune Cytopenias Including Autoimmune Hemolytic Anemia, Immune Thrombocytopenia, and Chronic Idiopathic/Autoimmune Neutropenia
NCT05931718
Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
NCT07224360
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OM336 Dose Escalation
Participants will receive OM336 via subcutaneous injection in ascending dose cohorts
OM336
OM336 is an engineered bispecific antibody directed against BCMA and CD3
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OM336
OM336 is an engineered bispecific antibody directed against BCMA and CD3
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Relapsed/refractory after ≥1 prior treatment
* Body weight ≥ 55 kg
* Willing to comply with and study requirements and procedures
Exclusion Criteria
* Clinically significant infection within 3 months of screening
* Major surgery or splenectomy within 3 months of screening or planned during the study
* Pregnant or breastfeeding
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ouro Medicines
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Canberra Hospital
Canberra, Australian Capital Territory, Australia
Liverpool Hospital
Sydney, New South Wales, Australia
Icon Cancer Center South Brisbane
Brisbane, Queensland, Australia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OM336-AIC-1001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.